Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Food and Drug Administration (FDA) - January 16, 2003
The proposed label warnings would also advise consumers that the use of vaginal contraceptives containing nonoxynol 9 can increase vaginal irritation, which may actually increase the possibility of transmitting the AIDS virus and other STDs from infected partners.
FDA's proposed labeling statements are based on recent studies using nonoxynol 9, including data from a four-year World Health Organization study of 991 HIV-negative sex workers in Africa and Thailand. The study, whose final results were recently published, showed nonoxynol 9 to be ineffective in the prevention of HIV infection.
Nonoxynol 9 works as a vaginal contraceptive by damaging the cell membrane of sperm. It has been shown in laboratory studies to damage the cell walls of certain organisms that cause STDs and to be active against some STD-causing bacteria and viruses. On the basis of data that are described in the labeling proposal, FDA believes that this same membrane-damaging effect can harm the cell lining of the vagina and cervix, thereby increasing the risk of STD transmission.
FDA's proposed warning labeling for these vaginal contraceptive products containing nonoxynol 9 is being published in today's Federal Register. The agency is requesting public comment, for the next 90 days, on the proposed labeling statements and on the most effective way to present this new warning. Interested parties may send written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments to http://www.accessdata.fda.gov/scripts/oc/dockets/comments/CommentsMain.cfm?DocketNum=80N-0280&SUBMIT='CONTINUE'.
####
FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.
T03-05 January 16, 2003 Consumer Inquiries: 888-INFO-FDA Media Inquiries: 301-827-6242
Office of Public Affairs
030116
FD030104
SOURCE: Food and Drug Administration (FDA).
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .